Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
This image was generated by AI and may not depict real events.
Aktis Oncology has appointed Glenn Gormley, MD, PhD, to its Board of Directors and as co-chair of its Science and Technology Committee. Gormley brings over three decades of biopharmaceutical leadership experience, particularly in oncology innovation.
Aktis Oncology, a clinical-stage oncology company, has appointed Glenn Gormley, MD, PhD, as an independent director to its Board of Directors. Gormley will also serve as co-chair of the Company's newly established Science and Technology Committee. He brings extensive experience in global biopharmaceutical leadership and oncology innovation. Gormley's background includes leading the discovery and development of novel antibody drug conjugate formats. Aktis is focused on expanding the potential of targeted radiopharmaceuticals. The company has developed a proprietary miniprotein radioconjugate platform to deliver radioisotopes to targeted tumors. Gormley's appointment coincides with the planned departure of current Board members Helen Kim and Oleg Nodelman.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.